Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06463665 |
| Title | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) ((VIRO-25)) |
| Acronym | (VIRO-25) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Genelux Corporation |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |